{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:08:35Z","timestamp":1791295715306,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,30]],"date-time":"2017-08-30T00:00:00Z","timestamp":1504051200000},"content-version":"vor","delay-in-days":394,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.jacc.2016.05.083","type":"journal-article","created":{"date-parts":[[2016,8,22]],"date-time":"2016-08-22T19:15:26Z","timestamp":1471893326000},"page":"967-976","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":241,"title":["Aspirin and Cancer"],"prefix":"10.1016","volume":"68","author":[{"given":"Paola","family":"Patrignani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Patrono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2016.05.083_bib1","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"2014 AHA\/ACC guideline for the management of patients with non\u2013ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"64","author":"Amsterdam","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2016.05.083_bib2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","article-title":"2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2016.05.083_bib3","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1056\/NEJMp1213380","article-title":"Aspirin in the secondary prevention of cardiovascular disease","volume":"368","author":"Parekh","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2016.05.083_bib4","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jacc.2015.05.012","article-title":"The multifaceted clinical readouts of platelet inhibition by low-dose aspirin","volume":"66","author":"Patrono","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2016.05.083_bib5","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1093\/eurheartj\/eht058","article-title":"Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both or neither?","volume":"34","author":"Patrono","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2016.05.083_bib6","doi-asserted-by":"crossref","first-page":"e637S","DOI":"10.1378\/chest.11-2306","article-title":"Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed. American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Vandvik","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2016.05.083_bib7","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","article-title":"European guidelines on cardiovascular disease prevention in clinical practice (version 2012)","volume":"33","author":"Perk","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2016.05.083_bib8","doi-asserted-by":"crossref","first-page":"836","DOI":"10.7326\/M16-0577","article-title":"Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement","volume":"164","author":"Bibbins-Domingo","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2016.05.083_bib9","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrclinonc.2011.199","article-title":"The role of aspirin in cancer prevention","volume":"9","author":"Thun","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jacc.2016.05.083_bib10","first-page":"4399","article-title":"Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study","volume":"48","author":"Kune","year":"1988","journal-title":"Cancer Res"},{"key":"10.1016\/j.jacc.2016.05.083_bib11","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(12)70112-2","article-title":"Effects of regular aspirin on long-term cancer incidence and metastasis: a systemic comparison of evidence from observational studies versus randomised trials","volume":"13","author":"Algra","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jacc.2016.05.083_bib12","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/jnci\/djn485","article-title":"Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials","volume":"101","author":"Cole","year":"2009","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jacc.2016.05.083_bib13","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1056\/NEJMoa0801297","article-title":"Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome","volume":"359","author":"Burn","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2016.05.083_bib14","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/S0140-6736(11)61049-0","article-title":"Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial","volume":"378","author":"Burn","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2016.05.083_bib15","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/S0140-6736(11)61720-0","article-title":"Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials","volume":"379","author":"Rothwell","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2016.05.083_bib16","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/jnci\/94.4.252","article-title":"Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues","volume":"94","author":"Thun","year":"2002","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jacc.2016.05.083_bib17","doi-asserted-by":"crossref","first-page":"s25","DOI":"10.1161\/ATVBAHA.107.160481","article-title":"Aspirin: promise and resistance in the new millennium","volume":"28","author":"Patrono","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2016.05.083_bib18","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","article-title":"Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials","volume":"382","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2016.05.083_bib19","unstructured":"Institute of Genetic Medicine, Newcastle University, and International Center for Life. CaPP3 Cancer Prevention Programme. Available at: http:\/\/www.capp3.org. Accessed June 20,\u00a02016."},{"key":"10.1016\/j.jacc.2016.05.083_bib20","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0140-6736(07)60747-8","article-title":"Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and\u00a0observational studies","volume":"369","author":"Flossmann","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2016.05.083_bib21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(10)62110-1","article-title":"Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials","volume":"377","author":"Rothwell","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2016.05.083_bib22","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/S0140-6736(12)60209-8","article-title":"Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials","volume":"379","author":"Rothwell","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2016.05.083_bib23","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1056\/NEJM199110173251605","article-title":"Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin","volume":"325","author":"Clarke","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2016.05.083_bib24","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-159-2-201307160-00002","article-title":"Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial","volume":"159","author":"Cook","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2016.05.083_bib25","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1172\/JCI110576","article-title":"Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects","volume":"69","author":"Patrignani","year":"1982","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacc.2016.05.083_bib26","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/jth.12637","article-title":"Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action","volume":"12","author":"Patrignani","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jacc.2016.05.083_bib27","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2016.05.083_bib28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/978-3-642-30331-9_3","article-title":"Mode of action of aspirin as a chemopreventive agent","volume":"191","author":"Dovizio","year":"2013","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.jacc.2016.05.083_bib29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1172\/JCI200113418","article-title":"Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs","volume":"108","author":"Patrono","year":"2001","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacc.2016.05.083_bib30","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/219068a0","article-title":"In\u00a0vitro acetylation of plasma proteins, enzymes and DNA by aspirin","volume":"219","author":"Pinckard","year":"1968","journal-title":"Nature"},{"key":"10.1016\/j.jacc.2016.05.083_bib31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1124\/mol.113.084988","article-title":"Pharmacological inhibition of platelet-tumor cell cross-talk prevents platelet-induced overexpression of cyclooxygenase-2 in HT29 human colon carcinoma cells","volume":"84","author":"Dovizio","year":"2013","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jacc.2016.05.083_bib32","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1194\/jlr.M041533","article-title":"Human platelets generate phospholipid-esterified prostaglandins via cyclooxygenase-1 that are inhibited by low dose aspirin supplementation","volume":"54","author":"Aldrovandi","year":"2013","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2016.05.083_bib33","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1538-7836.2011.04194.x","article-title":"Release of sphingosine-1-phosphate from human platelets is dependent on thromboxane formation","volume":"9","author":"Ulrych","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jacc.2016.05.083_bib34","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1182\/blood-2003-08-2804","article-title":"Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions","volume":"103","author":"Coppinger","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2016.05.083_bib35","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1182\/blood.V94.11.3791","article-title":"Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules","volume":"94","author":"Heijnen","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2016.05.083_bib36","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/ncb1596","article-title":"Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells","volume":"9","author":"Valadi","year":"2007","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.jacc.2016.05.083_bib37","doi-asserted-by":"crossref","first-page":"723419","DOI":"10.1155\/2012\/723419","article-title":"Prostaglandins in cancer cell adhesion, migration, and invasion","volume":"2012","author":"Menter","year":"2012","journal-title":"Int J Cell Biol"},{"key":"10.1016\/j.jacc.2016.05.083_bib38","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.cell.2015.08.015","article-title":"Cyclooxygenase-dependent tumor growth through evasion of immunity","volume":"162","author":"Zelenay","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.jacc.2016.05.083_bib39","first-page":"4705","article-title":"Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice","volume":"60","author":"Chulada","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.jacc.2016.05.083_bib40","doi-asserted-by":"crossref","first-page":"12098","DOI":"10.1073\/pnas.0603235103","article-title":"15-Hydroxyprostaglandin dehydrogenase is an in\u00a0vivo suppressor of colon tumorigenesis","volume":"103","author":"Myung","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacc.2016.05.083_bib41","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/0016-5085(94)90246-1","article-title":"Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas","volume":"107","author":"Eberhart","year":"1994","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1016\/j.jacc.2016.05.083_bib42","doi-asserted-by":"crossref","first-page":"S211","DOI":"10.1016\/S0016-5085(16)30783-1","article-title":"Direct\u00a0evidence for long-lasting acetylation of cyclooxygenase-1 associated with reduction of colorectal mucosa prostaglandin E2 levels and ribosomal protein S6 phosphorylation by low-dose aspirin in subjects undergoing colorectal cancer screening","volume":"150","author":"Patrignani","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jacc.2016.05.083_bib43","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrc3004","article-title":"Contribution of platelets to tumour metastasis","volume":"11","author":"Gay","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jacc.2016.05.083_bib44","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ccr.2011.09.009","article-title":"Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis","volume":"20","author":"Labelle","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jacc.2016.05.083_bib45","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.8655","article-title":"Aspirin prevents colorectal cancer metastasis in\u00a0mice by splitting the crosstalk between platelets and tumor cells","author":"Guillem-Llobat","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jacc.2016.05.083_bib46","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2016.05.083_bib47","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/annonc\/mdu225","article-title":"Estimates of benefits and harms of prophylactic use of aspirin in the general population","volume":"26","author":"Cuzick","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jacc.2016.05.083_bib48","doi-asserted-by":"crossref","first-page":"361","DOI":"10.7326\/0003-4819-146-5-200703060-00008","article-title":"Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U.S. Preventive Services Task Force recommendation statement","volume":"146","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2016.05.083_bib49","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jacc.2014.03.049","article-title":"Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology Working Group on Thrombosis","volume":"64","author":"Halvorsen","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2016.05.083_bib50","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1053\/j.gastro.2015.11.018","article-title":"Where do we stand with aspirin for the prevention of colorectal cancer? The USPTF recommendations","volume":"150","author":"Chan","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jacc.2016.05.083_bib51","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1056\/NEJMoa1207756","article-title":"Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival","volume":"367","author":"Liao","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2016.05.083_bib52","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1001\/jama.2015.1815","article-title":"Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants","volume":"313","author":"Nan","year":"2015","journal-title":"JAMA"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109716336075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109716336075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T12:03:09Z","timestamp":1601035389000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109716336075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":52,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S0735109716336075"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2016.05.083","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aspirin and Cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2016.05.083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by the American College of Cardiology Foundation","name":"copyright","label":"Copyright"}]}}